Intravenous transplantation of bone marrow-derived mesenchymal stromal cells in patients with multiple sclerosis, a phase I/IIa, double blind, randomized controlled study

• Published in: Multiple sclerosis and related disorders 2023-10, Vol.78, p.104895-104895, Article 104895
• Main Authors: Nabavi, Seyed Massood, Karimi, Shahedeh, Arab, Leila, Aghdami, Nasser, Joghtaei, Neda, Maroufizadeh, Saman, Jarooghi, Neda, Bolurieh, Tina, Abbasi, Fatemeh, Mardpour, Soura, Azimyian, Vajihe, Moeininia, Fatemeh, Sanjari, Leila, Hosseini, Seyedeh Esmat, Vosough, Massoud
• Format: Article
• Language: English
• Subjects: Cell therapy; Mesenchymal stromal cells; MSCs in MS; Multiple sclerosis; Regenerative medicine
• ISSN: 2211-0348; 2211-0356
• DOI: 10.1016/j.msard.2023.104895

Multiple sclerosis (MS) is a progressive, demyelinating neurodegenerative disease of the central nervous system. MS is immune-mediated and leads to disability especially in young adults. Even though 18 MS therapy drugs were approved, they slightly inhibit disease progression and do not induce regeneration and repair in the nervous system. Mesenchymal stromal cells (MSCs) have emerged as a new therapeutic modality in regenerative medicine and tissue engineering due to their immunomodulation and bio regenerative properties. We have designed a randomized, controlled clinical trial to assess safety and possible efficacy of MSC application in MS patients. Twenty-one MS patients were enrolled. Patients were allocated in two distinct groups: treatment group, which received systemic transplantation of autologous bone marrow-derived MSCs, and control group, which received placebo at the first injections. Patients in control group received MSCs at the second injection while the treatment group received placebo. All the patients were followed for 18 months. Follow-ups included regular visits, laboratory evaluation, and imaging analysis. Control patients received MSCs six month after treatment group. No severe immediate or late adverse events were observed in both groups after interventions. We did not find any significant differences in the rate of relapses, Expanded Disability Status Scale (EDSS) score, cognitive condition, Magnetic Resonance Imaging (MRI) findings, or any biomarkers of cerebrospinal fluid between the two groups and in each group before and after cell infusion. Transplantation of autologous bone marrow-derived mesenchymal stromal cells is safe and feasible. The efficacy of transplantation of these cells should be evaluated through designing randomized clinical trials with larger sample sizes, different administration routes, other cell types (allogeneic adipose derived MSCs, allogeneic Wharton's jelly derived MSCs …), repeated injections, and longer follow-up periods.